Elevate-TN: Impact of First-Year Dose Modifications in Patients with Treatment-Naive Chronic Lymphocytic Leukemia Treated with Acalabrutinib

被引：0

作者：

Follows, George ^{[1
]}

Ferrajoli, Alessandra ^{[2
]}

Byrd, John C. ^{[3
]}

Shaw, Bob ^{[4
]}

Nozaki, Kenji ^{[5
]}

Stewart, Katherine ^{[6
]}

De Miranda, Paulo Andre P. Palhares ^{[6
]}

Sharman, Jeff P. ^{[7
]}

机构：

[1] Addenbrookes Hosp NHS Trust, Dept Haematol, Cambridge, England

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA

[4] AstraZeneca, Cambridge, England

[5] AstraZeneca, Osaka, Japan

[6] AstraZeneca, Gaithersburg, MD USA

[7] Willamette Valley Canc Inst & Res Ctr US Oncol Re, Eugene, OR USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174767

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Acalabrutinib ± Obinutuzumab Vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Patel, Krish
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Hughes, Marie
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Follows, George
Walker, Patricia A.
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Byrd, John C.
Ferrant, Emmanuelle
Ferrajoli, Alessandra
Wierda, William G.
Munugalavadla, Veerendra
Wachira, Catherine Wangui
Wun, Chuan-Chuan
Woyach, Jennifer A.
BLOOD, 2023, 142
[2] Acalabrutinib ± obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up
Martens, U. M.
Sharman, J. P.
Egyed, M.
Jurczak, W.
Skarbnik, A.
Pagel, J. M.
Kamdar, M.
Munir, T.
Corbett, G.
Fogliatto, L. M.
Herishanu, Y.
Banerji, V
Coutre, S.
Walker, P.
Karlsson, K.
Ghia, P.
Janssens, A.
Wierda, W. G.
Patel, P.
Wang, M. H.
Byrd, J. C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 106 - 106
[3] Acalabrutinib ± Obinutuzumab vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steven
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Woyach, Jennifer A.
Ferrant, Emmanuelle
Wierda, William G.
Munugalavadla, Veerendra
Patel, Priti
Wang, Min Hui
Byrd, John C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S318 - S319
[4] Acalabrutinib ± obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.
Sharman, Jeff Porter
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Kamdar, Manali K.
Munir, Talha
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steve E.
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Wierda, William G.
Patel, Priti
Wang, Min Hui
Byrd, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Acalabrutinib ± Obinutuzumab vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 5-Year Follow-Up of ELEVATE-TN
Martens, Uwe
Sharman, Jeff
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan P.
Kamdar, Manali
Munir, Talha
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Ferrant, Emmanuelle
Munugalavadla, Veerendra
Yu, Ting
Wang, Min Hui
Woyach, Jennifer
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 167
[6] A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia
Kittai, Adam
Allan, John
James, Dan
Bridge, Helen
Miranda, Miguel
Yong, Alan
Fam, Fady
Roos, Jack
Shetty, Vikram
Skarbnik, Alan
Davids, Matthew
LEUKEMIA & LYMPHOMA, 2023, 64 : S82 - S83
[7] Acalabrutinib in treatment-naive chronic lymphocytic leukemia
Byrd, John C.
Woyach, Jennifer A.
Furman, Richard R.
Martin, Peter
O'Brien, Susan
Brown, Jennifer R.
Stephens, Deborah M.
Barrientos, Jacqueline C.
Devereux, Stephen
Hillmen, Peter
Pagel, John M.
Hamdy, Ahmed
Izumi, Raquel
Patel, Priti
Wang, Min Hui
Jain, Nitin
Wierda, William G.
BLOOD, 2021, 137 (24) : 3327 - 3338
[8] Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steven
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Woyach, Jennifer A.
Ferrant, Emmanuelle
Wierda, William G.
Munugalavadla, Veerendra
Yu, Ting
Wang, Min Hui
Byrd, John C.
LEUKEMIA, 2022, 36 (04) : 1171 - 1175
[9] Acalabrutinib ± Obinutuzumab versus Obinutuzumab plus Chlorambucil in Patients with therapy-naive chronic lymphocytic Leukemia: ELEVATE-TN 5-Year Follow-up
Martens, U. M.
Sharman, J. P.
Egyed, M.
Jurczak, W.
Skarbnik, A.
Kamdar, M.
Munir, T.
Fogliatto, L. M.
Herishanu, Y.
Banerji, V
Follows, G.
Walker, P.
Karlsson, K.
Ghia, P.
Janssens, A.
Ferrant, E.
Munugalavadla, V
Yu, T.
Wang, M. H.
Woyach, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 16 - 17
[10] PATIENT-REPORTED OUTCOMES FROM THE PHASE 3, RANDOMIZED STUDY OF ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB FOR TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA (ELEVATE-TN)
Walker, P.
Sharman, J. P.
Jurczak, W.
Munir, T.
Banerji, V
Coutre, S.
Woyach, J.
Salles, G.
Wierda, W. G.
Patel, P.
Wang, M. H.
Emeribe, U.
Flood, E.
Byrd, J. C.
Ghia, P.
VALUE IN HEALTH, 2021, 24 : S3 - S4

← 1 2 3 4 5 →